MedTrace Logo

To Explore the Effect of GH Pretreatment on Clinical Outcomes in Patients With Low Ovarian Reserve

NCT04384783 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2020-05-21

No results posted yet for this study

Summary

Growth hormone (GH) has been used in the field of assisted reproduction technology for over 30 years. Studies for GH have been exploring in the applicable population, drug dosage, starting time and time limitation. In previous clinical applications, it worked as an adjuvant drug for improving ovarian reactivity. With the development of basic research and clinical applications, the improvement effect on egg quality is gradually recognized. However, which protocol of GH may work well and maximize the clinical effect remains mystery. The investigators' previous self-controlled retrospective research about 380 cases treated with GH found that the average daily injection of GH dose of 2IU for about 6 weeks can significantly improve embryo quality and clinical pregnancy outcomes of the patients with low ovarian response. The new POSEIDON standard clearly groups people with low prognosis and better classifies heterogeneous people, which may help classifying the specific subgroup that benefit most from GH of poor ovarian response (POR). The investigators design a prospective cohort study to explore whether GH low-dose long-term pretreatment can improve the outcome of assisted pregnancy and its possible mechanism in people with low ovarian reserve.

Conditions

  • GH
  • Low Ovarian Reserve

Interventions

DRUG

growth hormone

growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.

Sponsors & Collaborators

  • Guangzhou First People's Hospital

    lead OTHER

Principal Investigators

  • meihong Cai, master · Guangzhou First People's Hospital

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2022-04-30
Completion
2022-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04384783 on ClinicalTrials.gov